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A single injection of HPV16 L1 virus-like particles induced potent CD8-mediated protection from tumor challenge by C3
cells, a line derived from embryonic mouse cells transfected with the HPV16 genome. L1 RNA, but not protein, was detected
biochemically in C3 cells. These results indicate that low-level expression of HPV16 L1 can occur in proliferating cells and
serve as a tumor vaccine target. Although L1 expression is generally thought to be restricted to terminally differentiated
epithelial cells, these results suggest that additional analysis for low-level L1 expression in proliferating cells of HPV-induced
lesions is warranted and might help in predicting the clinical potential of HPV L1 virus-like particle-based vaccines. © 1998
Academic Press
INTRODUCTION
The strong association between cervical cancer and
HPV16 infection has generated considerable interest in
developing a safe and effective therapeutic vaccine to
eliminate infection by this virus. Because E6 and E7 are
selectively maintained and expressed during malignant
progression, most vaccine strategies have focused on
these two viral targets (reviewed in Kast et al., 1996;
Schiller and Okun, 1996). In contrast, the virion capsid
proteins L1 and L2 are expressed in terminally differen-
tiated squamous epithelial cells but are not thought to be
expressed in proliferating cells (Taichman and LaPorta,
1987). We recently developed chimeric HPV16 virus-like
particles (VLPs) in which the full-length HPV16 E7 protein
is incorporated into L1/L2 VLPs via fusion to the carboxyl
terminus of L2. In addition to eliciting the production of
high-titer neutralizing antibodies, immunization with
these chimeric VLPs (but not the parental L1/L2 VLPs), in
the absence of adjuvant, protected mice from tumor
challenge with the TC-1 cell line (Greenstone et al.,
1998). This cell line expresses HPV16 E7 but not HPV16
L1 (Lin et al., 1996).
Another established HPV16 tumor vaccine model is
based on the C3 tumorigenic cell line, which was gen-
erated from full-length HPV16 plus EJras transformed
C57Bl/6 (B6) mouse embryo cells (Feltkamp et al., 1993).
C3 has previously been used extensively to examine
antitumor immune responses to HPV16 E6 and E7 pep-
tides (Feltkamp et al., 1993, 1995). In an attempt to dem-
onstrate E7-specific antitumor responses against C3
cells after vaccination with the E7 chimeric VLPs, we
obtained unexpected results indicating that these prolif-
erating tumor cells express sufficient L1 to serve as a
target for protective antitumor immune responses.
RESULTS
In an attempt to demonstrate E7-specific antitumor
immune responses to E7 chimeric VLPs using an HPV16
transformed cell line, we challenged B6 mice subcuta-
neously with C3 cells 2 weeks after subcutaneous vac-
cination with a single 50-mg dose of HPV16 L1/L2-E7
chimeric VLPs in incomplete Freund’s adjuvant (IFA).
Protection from tumor challenge was observed in these
mice, unlike control mice vaccinated with IFA alone or
mice vaccinated with 10 mg of an irrelevant peptide
antigen (SGPSNTPPEI) (Kast et al., 1989) in IFA (Table 1,
Exp. 1). The protection induced by the chimeric VLPs was
comparable to that obtained with the positive control
antigen, 10 mg of the E7 peptide RAHYNIVTF in IFA
(Feltkamp et al., 1993). Unexpectedly, a single 50-mg
dose of the parental HPV16 L1/L2 VLPs (composed of
HPV16 L1 plus HPV16 L2) (Kirnbauer et al., 1993) also
gave complete protection in this experiment. In contrast
to RAHYNIVTF, the VLPs induced a protective response
when a single 50-mg (Exp. 2) or 30-mg (Exp. 3) dose was
administered in the absence of adjuvant. There was no
significant difference in the degree of protection elicited
by HPV16 L1 VLPs compared with HPV16 L1/L2 VLPs
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(using a 30-mg dose, Exp. 3), indicating that a response
to L1 was sufficient for protection. Protection also was
seen after two subcutaneous vaccinations (2 weeks
apart) with 20 mg of HPV16 L1/L2 VLPs but not after two
vaccinations with 20 ng of VLPs (Exp. 4).
In contrast to the HPV16 VLPs, BPV1 L1/L2 VLPs that
are 49% identical in L1 amino acid sequence with HPV16
(Kirnbauer et al., 1992) did not protect against C3 chal-
lenge after a single vaccination with 50 mg in either the
presence or absence of adjuvant (Exp. 2). Similarly, no
protection was observed after two sequential vaccina-
tions with 20 mg or 20 ng of BPV VLPs (Exp. 4). These
results indicated that the protective immune response
was specific for HPV16 L1.
The specificity of the tumor protection induced by
HPV16 VLPs was examined further in experiments using
the AR6 tumorigenic cell line. As with C3, AR6 was
derived from B6 mouse embryo cells containing EJras,
except that it was generated after transfection with hu-
man adenovirus type 5 E1A rather than with the HPV16
genome (Toes et al., 1995). HPV16 L1/L2 VLP vaccination
did not protect against challenge with AR6 tumor cells
(five of eight mice were tumor positive), whereas the
positive control antigen, inactivated SAMB7 cells
(Schoenberger et al., 1998) presenting E1A peptides, was
protective (none of six mice were tumor positive). The
lack of protection from HPV16 L1/L2 VLP immunization
was significant when compared to immunization with the
positive control SAMB7 cells (P 5 0.031). Therefore,
protection after HPV16 VLP vaccination was specific to
the HPV16 transfected embryo cells.
To examine the immunological mechanism responsi-
ble for the protection elicited by the VLPs, B6 mice were
depleted of CD41 or CD81 T cells by injection of a
CD4-specific monoclonal antibody (GK1.5) or a CD8-spe-
cific monoclonal antibody (2.43), respectively (Dialynas
et al., 1983; Sarmiento et al., 1980). FACS analysis of
peripheral blood mononuclear cells indicated that effec-
tive depletion (.99%) of CD41 or CD81 T cells by GK1.5
and 2.43, respectively, had occurred (data not shown). No
protection was observed when the CD8-depleted mice
were vaccinated with HPV16 L1/L2 VLPs and challenged
with C3 cells (Fig. 1). In contrast, VLP vaccination com-
pletely protected the CD4-depleted mice from tumor
challenge (Fig. 1). Therefore, we conclude that the anti-
tumor response induced by the VLPs is mediated by
CD81 CTLs.
Our finding that HPV16 VLPs could induce an L1-
specific protective immune response against C3 chal-
lenge was unexpected because L1 is generally thought
to be expressed only in terminally differentiated epithe-
lial cells (Stoler et al., 1992; Taichman and LaPorta, 1987),
and C3 is a transformed embryo-derived cell line. How-
ever, the fact that C3 was generated after transfection of
TABLE 1
Protection from Challenge with C3 Tumorigenic Cell Line
Antigen Dosage Adjuvant Tumors P value
Exp. 1 PBS — IFA 5/9 Ref.
SGPSNTPPEI 10 mg 3 1 IFA 4/7 1.000
RAHYNIVTF 10 mg 3 1 IFA 0/8 0.029
16 L1/L2 50 mg 3 1 IFA 0/8 0.029
16 L1/L2-E7 50 mg 3 1 IFA 0/8 0.029
Exp. 2 PBS — IFA 10/12 Ref.
RAHYNIVTF 10 mg 3 1 IFA 3/10 0.027
16 L1/L2 50 mg 3 1 IFA 3/8 0.062
B L1/L2 50 mg 3 1 IFA 6/8 0.999
RAHYNIVTF 10 mg 3 1 PBS 8/8 Ref.
16 L1/L2 50 mg 3 1 PBS 2/6 0.015a
B L1/L2 50 mg 3 1 PBS 6/6 0.999a
Exp. 3 PBS — PBS 8/10 Ref.
RAHYNIVTF 10 mg 3 2 IFA 4/10 0.170
16 L1 30 mg 3 2 PBS 1/10 0.003
16 L1/L2 30 mg 3 2 PBS 0/10 ,0.001
Exp. 4 PBS — PBS 8/10 Ref.
16 L1/L2 20 mg 3 2 PBS 2/10 0.023
16 L1/L2 20 ng 3 2 PBS 8/10 1.000
B L1/L2 20 mg 3 2 PBS 8/10 1.000
B L1/L2 20 ng 3 2 PBS 10/10 0.474
Note. Mice were immunized with VLPs as indicated (16 5 HPV16; B 5 BPV1; L1, L1/L2, and L1/L2-E7 refer to VLPs containing the respective
proteins). 3 1 indicates single immunization; 3 2, two immunizations 2 weeks apart; IFA, incomplete Freund’s adjuvant; PBS, phosphate-buffered
saline; Ref., reference. Tumor take was assessed on day 93 after challenge for Exp. 1, day 67 after challenge for Exp. 2, day 73 after challenge for
Exp. 3, and day 46 after challenge for Exp. 4.
a Compared with mice immunized with RAHYNIVTF in PBS.
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the full-length HPV16 genome raised the possibility that
HPV16 L1 polypeptides were expressed, processed, and
presented in the context of MHC class I molecules in C3
cells. We therefore sought evidence for L1 expression in
this line, using a standard RT-PCR protocol. Amplified
products of the predicted length were detected for a 59
segment (300 bp), a 39 segment (300 bp), and, to a lesser
extent, the almost full-length transcript (1489 of 1518 bp)
(Fig. 2). Because no PCR products were detected when
the reverse transcriptase was omitted from the reactions,
we conclude that L1 RNA rather than L1 DNA was the
initial template for amplification.
Having detected L1 RNA, we sought direct evidence
for L1 protein in C3 cells. In initial studies, L1 protein was
not detected in immunofluorescent staining of fixed C3
cells or in immunoblots of C3 lysates using L1-specific
monoclonal or polyclonal sera that recognize either na-
tive or denatured L1 (data not shown). However, because
these assays measure steady-state levels of protein,
they did not address the possibility that substantial
amounts of L1 were synthesized but rapidly degraded.
Because the peptides required for class I presentation
are usually generated by proteolysis in proteasome com-
plexes (Brown et al., 1991; Glynne et al., 1991), rapid
degradation would be compatible with, and possibly
even beneficial for, class I presentation. In an attempt to
detect short-lived L1 protein species, we conducted L1
immunoprecipitations of C3 extracts that had been ra-
diolabeled with 35S-cysteine and 35S-methionine for
short periods (15 and 60 min). To maximize sensitivity,
combined rabbit antisera raised against native HPV16
VLPs and denatured HPV16 VLPs or pooled monoclonal
antibodies recognizing both native and denatured L1
were used in the immunoprecipitation reactions. How-
ever, neither full-length nor truncated L1 protein was
detected after subjecting the precipitates to SDS–PAGE
followed by autoradiography, even after exposure of the
autoradiographs for several weeks (data not shown). We
suspect that the L1 protein is expressed at low levels in
C3 cells and too rapidly degraded to be detected by
standard immunochemical methods.
DISCUSSION
In this study, we determined that VLPs can induce a
CD8-restricted antitumor response specific for HPV16 L1.
Consistent with this finding is a recent report demon-
strating an increase in the relative number of splenic
CD81 T cells in mice immunized with HPV16 L1 VLPs
(Dupuy et al., 1997). Evidence for MHC class I restriction
was also found in our recent study of HPV16 L1/L2-
HPV16E7 chimeric VLPs, where immunization with the
FIG. 1. Protection from C3 challenge after depletion of CD41 or CD81 T cells. CD41 and CD81 T cells were depleted by injection of monoclonal
antibody GK1.5 and monoclonal antibody 2.34, respectively (Dialynas et al., 1983; Sarmiento et al., 1980). Depleted and control mice were vaccinated
with 50 mg of HPV16 L1/L2 VLPs. Imm. indicates immunogen; n, number of animals per group.
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chimeric VLPs (but not L1 or L1/L2 VLPs) provided E7-
specific tumor protection from TC-1 cell challenge in
class II knockout but not in b2-microglobulin or perforin
knockout mice (Greenstone et al., 1998). Although CD4-
restricted responses were not required for tumor protec-
tion in either the C3 or TC-1 assays, the preferential
induction of a Th1 type T-helper response to VLP vacci-
nation is likely to promote proliferation of VLP-specific
CD81 T cells under normal conditions (Dupuy et al.,
1997).
The precise mechanism by which papillomavirus VLPs
were able to induce CD8-restricted responses remains
uncertain. MHC class I-mediated cytotoxic T lymphocyte
(CTL) responses are usually induced by endogenously,
rather than exogenously, presented antigens or by using
viral vectors like vaccinia virus expressing HPV16 L1
DNA (Zhou et al., 1991). However, enhancement of class
I-restricted responses to an exogenous antigen by pre-
sentation in a particulate form has been documented,
although the smallest particles investigated were 10-fold
larger than HPV VLPs (Kovacsovics-Bankowski et al.,
1993). In addition, VLPs may mimic authentic virions in
their ability to escape endocytic vesicles and enter the
cytoplasm after uptake. This would allow for degradation
of the L1 protein by the cytoplasmic proteasome com-
plexes with subsequent presentation by the normal TAP-
dependent mechanism (Brown et al., 1991; Glynne et al.,
1991).
Our results indicate that HPV16 L1 can, unexpectedly,
be expressed at sufficient levels in proliferating cells
transformed by the full-length HPV16 genome to serve as
a target of CTL. Furthermore, they demonstrate that VLPs
can efficiently induce a protective antitumor response
after a single low-dose injection in the absence of adju-
vant, even if there is a very low steady-state level of L1 in
the proliferating cells. Although the relevance of our in
vitro cell culture system to in vivo infection is unclear, our
findings should prompt a more comprehensive examina-
tion of L1 expression in infected basal cells of productive
lesions and the proliferating cells of more progressed
lesions, perhaps using sensitive and specific in situ
RT-PCR assays. This might aid in predicting the circum-
stances under which an L1 VLP vaccine might have
therapeutic effects in humans. Our findings further sup-
port the possibility that VLPs incorporating E7 peptides
or other antigens (Greenstone et al., 1998; Muller et al.,
1997) may be effective vehicles for generating antitumor
or antimicrobial CTL responses against other targets.
MATERIALS AND METHODS
Tumorigenicity assays
VLP vaccination and protection from C3 tumor chal-
lenge assays were performed essentially as described
previously (Feltkamp et al., 1993, 1995; Greenstone et al.,
1998). Mice were immunized subcutaneously with VLPs
or control peptide and challenged 14 days later with
0.5 3 106 C3 cells injected subcutaneously.
FIG. 2. Detection of HPV16 L1 transcripts in C3 cells. mRNAs from C57B1/6 mouse embryo cells (B6 MEC), C3 tumor cells, or HPV16 L1 recombinant
baculovirus-infected Sf9 cells (HPV16 L1-Sf9s) were purified using the Micro-FastTract Kit (InVitrogen Corp.). To remove any contaminating genomic
DNA, 130 U of RNase-free DNase (GIBCO BRL, Gaithersburg, MD) was added before RNA precipitation. Then, 100 ng of each mRNA was cycled twice
using the cDNA Cycle Kit (Invitrogen Corp.). The cDNAs were PCR amplified with HPV16 L1-specific primers. The reaction products shown in lanes
A, B, C, and D were generated using primers specific for the 59 end of HPV16 L1, the 39 end of HPV16 L1, the full-length HPV16 L1 (arrow), and the
full-length HPV16 E7, respectively.
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T cell depletion
B6 mice were depleted of CD41 or CD81 T cells by
injection of a CD4-specific monoclonal antibody (GK1.5)
or a CD8-specific monoclonal antibody (2.43), respec-
tively (Dialynas et al., 1983; Sarmiento et al., 1980). To
deplete CD41 or CD81 T cells in vivo, mice were injected
intraperitoneally on multiple days with 100 mg of the
appropriate monoclonal antibody. Relative to the first
immunization, the antibodies were administered on the
following days: 22, 1, 5, 11, and 27. Immunizations were
performed on days 0 and 12, and a challenge with 0.5 3
106 C3 cells was given on day 22.
RT-PCR
RT-PCRs were performed according to the manufac-
turer’s protocol (Invitrogen Corp., San Diego, CA). cDNAs
from L1 transcripts were amplified using primer pairs
specific for the 59 end (forward primer: 59-GGCTGC-
CTAGTGAGGCCACT-39, reverse primer: 59-ACCTCAA-
CACCTACACAGGC-39), the 39 end (forward primer: 59-
GACTGGAATTTTGGTCTACA-39, reverse primer: 59-
GCGTTTAGCAGTTGTAGAGG-39), or the full-length L1
gene (forward primer: 59-GGCTGCCTAGTGAGGCCACT-
39, reverse primer: 59-GCGTTTAGCAGTTGTAGAGG-39)
using AmpliTaq polymerase (Roche Molecular Systems,
Branchburg, NJ) under the recommended conditions.
Immunochemical assays for L1
Immunoprecipitation reactions were conducted as
previously described (Greenstone et al., 1998) using
combined rabbit antisera raised against native HPV16
VLPs and denatured HPV16 VLPs (No. 5085 and No.
5166, respectively) (Roden et al., 1996) or pooled mono-
clonal antibodies recognizing both native and denatured
L1 (H16.E70, H16.U4, H16.V5, H16.L4, H16.S1, H16.H5,
and H16.J4) (Christensen et al., 1996).
Statistical analysis
P values were determined using Fisher’s Exact Test
(two-tailed); P , 0.05 was deemed statistically signifi-
cant.
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